IVIg therapy in autoimmunity and related disorders: Our experience with a large cohort of patients

Autoimmunity

Volumn 38, Issue 2, 2005, Pages 123-137

  Shoenfeld, Yehuda ^a,b   Katz, Uriel ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Autoimmune; Cancer; Intravenous immunoglobulin; Systemic lupus erythematosus

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; DNA ANTIBODY; DOUBLE STRANDED DNA; GELATINASE B; HEPARIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 12; LA ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN; RO ANTIBODY; STEROID;

ABORTION; ANAPHYLAXIS; ANEMIA; ANTIPHOSPHOLIPID SYNDROME; ASEPTIC MENINGITIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BONE MARROW DISEASE; CANCER PATIENT; CANCER SURGERY; CENTRAL NERVOUS SYSTEM DISEASE; CHILL; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DIAPHORESIS; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ENDOCRINE OPHTHALMOPATHY; FATIGUE; FETUS WASTAGE; FEVER; HAND DISEASE; HEADACHE; HEART DISEASE; HEART INFARCTION; HEMATOLOGIC DISEASE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTION; INFLAMMATION; INOCULATION; KIDNEY FAILURE; LOW BACK PAIN; LUNG DISEASE; MEDICAL DECISION MAKING; MELANOMA CELL; MEMBRANOUS GLOMERULONEPHRITIS; MENTAL DISEASE; NAUSEA; NEPHRITIS; NEUROLOGIC DISEASE; NONHUMAN; ORBIT PSEUDOTUMOR; PETECHIA; PRURITUS; RECURRENT DISEASE; REVIEW; RODENT; SARCOMA CELL; SCLERODERMA; SIDE EFFECT; SKIN FIBROSIS; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; TREATMENT OUTCOME; URTICARIA; VASCULITIS; WEGENER GRANULOMATOSIS;

ADOLESCENT; ADULT; ANIMALS; AUTOIMMUNE DISEASES; COHORT STUDIES; EMBRYO LOSS; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MALE; MICE; MIDDLE AGED; PREGNANCY;

EID: 21044442418     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.1080/08916930500059633     Document Type: Review

References (127)

1. Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: Am update for clinicians. Transfusion 2003; 43:1460-1480.
2. Raouva L, Rovensky J, Shoenfeld Y. High dose intravenous immunoglobulins: A new step in the treatment of systemic lupus erythematosus. IMAJ 2000;:388-392.
3. Bar-Dayan Y, Karevi SV, Pashov A, Shoenfeld Y, Kazatchkine MD. Anti-inflammatory effects of intravenous immunoglobulin (IVIg). In: Eibl M, Huber H, editors. Symposium in immunology. Berlin: Springer-Verlag; 2002. p 171-184.
4. Blasczyk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993;341:789-790.
5. Kekow J, Reinhold D, Pap T, Ansorge S. Intravenous immunoglobulins and transforming growth factor beta. Lancet 1998;351:184-185.
6. Krause I, Wu R, Sherer Y, Patanik M, Peter JB, Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations - a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med 2002;12:133-139.
7. Abu-Shakra M, Buskila D, Shoenfeld Y. Introduction-idiotypes and anti-idiotypes. In: Shoenfeld Y, Kennedy RC, Ferrone S, editors. Idiotypes in medicine: Autoimmunity, infection and cancer. Amsterdam: Elsevier Science B.V. 1997. p 53-74.
8. Sherer Y, Levy Y, Shoenfeld Y. Intravenous immunoglobulin (IVIg) in autoimmune diseases - expanding indications and increasing specificity. pp. 85-91, Chapter 13. In: Heidt PJ, Rusch VD, van Der Waaij D, editors. Old Herborn University Seminar Monograph. Horborn Litterae. 2001.
9. Shoenfeld Y. 5th International Symposium on IVIG: IVIG in the third millennium. In: 2003 25-27 September; Interlaken; 2003.
10. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228-1231.
11. Rauova L, Lukac J, Levy Y, Rovensky J, Shoenfeld Y. High-dose intravenous immunoglobulins for lupus nephritis - a salvage immunomodulation. Lupus 2001;10:209-213.
12. Sherer Y, Levy Y, Shoenfeld Y. Intravenous immunoglobulin (IVIG) therapy in autoimmune diseases - SLE, anti-phospholipid syndrome, vasculitis. What is new? In: RHEUMA 21st (http://www.rheuma21st.com/index.html) 1999.
13. Sherer Y, Shoenfeld Y. Summary of an Expert Conference on the Use of IVIG. Expert Conference on the Use of IVIG; 2003 14-15 February; Berne. 2003.
14. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gamma-globulin. Lancet 1984;2:765-768.
15. Rossi F, Dietrich G, Kazatchkine MD. Antiidiotypic suppression of autoantibodies with normal polyspecific immunoglobulins. Res Immunol 1989;140:19-31.
16. Lacroix-Desmazes S, Mouthon L, Spalter SH, Kaveri S, Kazatchkine MD. Immunoglobulins and the regulation of autoimmunity through the immune network. Clin Exp Rheumatol 1996;14(Suppl. 15):S9-S15.
17. Mouthon L, Kaveri S, Kazatchkine M. Immune modulating effects of intravenous immunoglobulin (IVIg) in autoimmune diseases. Transfus Sci 1994;15:393-408.
18. Nydegger UE, Sultan Y, Kazatchkine MD. The concept of anti-idiotypic regulation of selected autoimmune diseases by intravenous immunoglobulin. Clin Immunol Immunopathol 1989;53:S72-S82.
19. Rossi F, Dietrich G, Kazatchkine MD. Anti-idiotypes against autoantibodies in normal immunoglobulins: Evidence for network regulation of human autoimmune responses. Immunol Rev 1989;110:135-149.
20. Krause I, Blank M, Kopolovic J, Afek A, Goldberg I, Tomer Y, et al. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J Rheumatol 1995;22:1068-1074.
21. Shoenfeld Y, Rauova L, Gilburd B, Kvapil F, Goldberg I, Kopolovic J, et al. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 2002;14:1303-1311.
22. Wu R, Shoenfeld Y, Sherer Y, Patnaik M, Matsuura E, Gilburd B, et al. Anti-idiotypes to oxidized LDL antibodies in intravenous immunoglobulin preparations - possible immunomodulation of atherosclerosis. Autoimmunity 2003; 36:91-97.
23. Krause I, Hacham S, Gilburd B, Damianovitch M, Blank M, Shoenfeld Y. Absence of anti-idiotypic antibodies in IVIG preparations to autoantibodies of rare autoimmune diseases. Clin Immunol Immunopathol 1995;77:229-235.
24. Levy Y, Sherer Y, Ahmed A, Fabbrizzi F, Terryberry J, Shen GQ, et al. Autoantibody level modification in adult patients with idiopathic thrombocytopenic purpura following intravenous immunoglobulin treatment. Nat Immun 1998;16:207-214.
25. Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabbrizzi F, et al. A study of 20 SLE patients with intravenous immunoglobulin - clinical and serologic response. Lupus 1999;8:705-712.
26. Rauova L, Rovensky J, Shoenfeld Y. Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins. Springer Semin Immunopathol 2001;23:447-457.
27. Braun-Moscovici Y, Furst DE. Immunoglobulin for rheumatic diseases in the twenty-first century: Take it or leave it? Curr Opin Rheumatol 2003;15:237-245.
28. Mollnes TE, Andreassen IH, Hogasen K, Hack CE, Harboe M. Effect of whole and fractionated intravenous immunoglobulin on complement in vitro. Mol Immunol 1997; 34:719-729.
29. Ronda N, Haury M, Nobrega A, Coutinho A, Kazatchkine MD. Selectivity of recognition of variable (V) regions of autoantibodies by intravenous immunoglobulin (IVIg). Clin Immunol Immunopathol 1994;70:124-128.
30. Bayry J, Lacroix-Desmazes S, Delignat S, Mouthon L, Weill B, Kazatchkine MD, et al. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48:3497-3502.
31. Sherer Y, Wu R, Krause I, Gorstein A, Levy Y, Peter JB, et al. Cytokine levels in various intravenous immunoglobulin (IVIg) preparations. Hum Antibodies 2001;10:51-53.
32. Sherer Y, Levy Y, Fabrizzi F, Shoenfeld Y. Immunomodulation of various autoimmune diseases by intravenous immunoglobulin. Drugs Today (Barc) 1999;35:513-518.
33. Krause I, Blank M, Sherer Y, Gilburd B, Kvapil F, Shoenfeld Y. Induction of oral tolerance in experimental antiphospholipid syndrome by feeding with polyclonal immunoglobulins. Eur J Immunol 2002;32:3414-3424.
34. Bakimer R, Guilburd B, Zurgil N, Shoenfeld Y. The effect of intravenous gamma-globulin on the induction of experimental antiphospholipid syndrome. Clin Immunol Immunopathol 1993;69:97-102.
35. Blank M, Levy Y, Amital H, Shoenfeld Y, Pines M, Genina O. The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum 2002;46:1689-1690.
36. Shoenfeld Y, Fishman P. Gamma-globulin inhibits tumor spread in mice. Int Immunol 1999;11:1247-1252.
37. Shapiro S, Shoenfeld Y, Gilburd B, Sobel E, Lahat N. Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages. Cancer 2002;95:2032-2037.
38. Lev S, Gilburd B, Lahat N, Shoenfeld Y. Prevention of tumor spread by matrix metalloproteinase-9 inhibition: Old drugs, new concept. Eur J Intern Med 2002;13:101-103.
39. Bar-Dayan Y, Barshack I, Blank M, Goldberg I, Levy Y, Kopolovic J, et al. Antibodies to the cytoplasm, cell membrane and nuclear membrane of malignant neoplasms in pooled normal human polyspecific immunoglobulin G. Int J Oncol 1999;15:1091-1096.
40. Merimsky O, Meller I, Inbar M, Bar-Yehuda S, Shoenfeld Y, Fishman P. A possible role for IVIg in the treatment of soft tissue sarcoma: A clinical case and an experimental model. Int J Oncol 2002;20:839-843.
41. Segal E, Shoenfeld Y. IVIG therapy in sepsis. Harefuah 2001;140:955-958.
42. Berchtold P, McMillan R. Intravenous immunoglobulin: New aspects of mechanism of action in chronic ITP In: PI, editor. Immunotherapy with intravenous immunoglobulins. London: Academic Press; 1991. p 245-252.
43. Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O'Rourke K, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 1999;28:800-807.
44. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2002:CD001090.
45. Douzinas EE, Pitaridis MT, Louris G, Andrianakis I, Katsouyanni K, Karmpaliotis D, et al. Prevention of infection in multiple trauma patients by high-dose intravenous immunoglobulins. Crit Care Med 2000;28:8-15.
46. Lev S, Shoenfeld Y. The family of metalloproteinases and their immunomodulatory significance. Harefuah 2002; 141:108-110.
47. Jormsjo S, Ye S, Moritz J, Walter DH, Dimmeler S, Zeiher AM, et al. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res 2000;86:998-1003.
48. Sela BA. The significance of matrix metalloproteinases in vascular biology. Harefuah 2001;140:134-138.
49. Nicoletti A, Kaveri S, Caligiuri G, Bariety J, Hansson GK. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Investig 1998;102:910-918.
50. Keren G, Keren P, Barshack I, Pri-Chen S, George J. The effect of intravenous immunoglobulins on intimal thickening in a mouse model of arterial injury. Atherosclerosis 2001;159:77-83.
51. Shoenfeld Y, Krause I. IVIG for Autoimmune, Fibrosis, and Malignant Conditions: Our experience with 200 Patients. J Clin Immunol 2004;24:107-114.
52. Hundt M, Manger K, Dorner T, Grimbacher B, Kalden P, Rascu A, et al. Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin. Rheumatology (Oxford) 2000;39:1301-1302.
53. Boletis JN, Ioannidis JP, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 1999; 354:569-570.
54. Hermosillo-Romo D, Brey RL. Neuropsychiatric involvement in systemic lupus erythemarosus. Curr Rheumatol Rep 2002;4:337-344.
55. Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB. Neuropsychiatric manifestations of systemic lupus erythematosus: Diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore) 1976;55:323-339.
56. Tomer Y, Shoenfeld Y. Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol 1992;10:391-393.
57. Sherer Y, Levy Y, Langevitz P, Lorber M, Fabrizzi F, Shoenfeld Y. Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol 1999;18:170-173.
58. Sherer Y, Levy Y, Shoenfeld Y. Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clin Rheumatol 1999;18:238-240.
59. Sherer Y, Langevitz P, Levy Y, Fabrizzi F, Shoenfeld Y. Treatment of chronic bilateral pleural effusions with intravenous immunoglobulin and cyclosporin. Lupus 1999;8:324-327.
60. Disla E, Rhim HR, Reddy A, Ramaprasad S, Taranta A. Reversible cardiogenic shock in a patient with lupus myocarditis. J Rheumatol 1993;20:2174.
61. Meissner M, Sherer Y, Levy Y, Chwalinska-Sadowska H, Langevitz P, Shoenfeld Y. Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis. Rheumatol Int 2000;19:199-201.
62. Ben-Chetrit E, Putterman C, Naparstek Y. Lupus refractory pleural effusion: Transient response to intravenous immunoglobulins. J Rheumatol 1991;18:1635-1637.
63. Welch TR, McAdams AJ, Beischel LS. Glomerulonephritis associated with complete deficiency of the fourth component of complement. Response to intravenous immunoglobulin. Arthritis Rheum 1995;38:1333-1337.
64. Welcker M, Helmke K. Immunologic therapy for glomerulonephritis with combined immunoadsorption and IVIG therapy. Immun Infekt 1995;23:140-141.
65. Winder A, Molad Y, Ostfeld I, Kenet G, Pinkhas J, Sidi Y. Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: Report of 2 cases. J Rheumatol 1993;20:495-498.
66. Lin CY, Hsu HC, Chiang H. Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Nephron 1989;53:303-310.
67. Corvetta A, Della Bitta R, Gabrielli A, Spaeth PJ, Danieli G. Use of high-dose intravenous immunoglobulin in systemic lupus erythematosus: Report of three cases. Clin Exp Rheumatol 1989;7:295-299.
68. Becker BN, Fuchs H, Hakim R. Intravenous immune globulin in the treatment of patients with systemic lupus erythematosus and end-stage renal disease. J Am Soc Nephrol 1995;5:1746-1750.
69. Pasatiempo AM, Kroser JA, Rudnick M, Hoffman BI. Acute renal failure after intravenous immunoglobulin therapy. J Rheumatol 1994;21:347-349.
70. Levy Y, Sherer Y, George J, Rovensky J, Lukac J, Rauova L, et al. Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum 2000;29:321-327.
71. Pilorget H, Bangui A, Adam M, Leverger G. Myelofibrosis regressing under corticotherapy and intravenous immunoglobulins in an infant. Arch Pediatr 1996;3:40-43.
72. Aarón A, Levy Y, Bar-Dayan Y, Afek A, Zandman-Goddard G, Skurnik Y, et al. Successful treatment of early secondary myelofibrosis in SLE with IVIG. Lupus 1997;6:408-411.
73. Asherson RA, Cervera R, Piette J, Shoenfeld Y. The antiphospholipid syndrome II: Autoimmune thrombosis. 1st ed. Amsterdam: Elsevier Science B.V. 2002.
74. Marzusch K, Dietl J, Klein R, Hornung D, Neuer A, Berg PA. Recurrent first trimester spontaneous abortion associated with antiphospholipid antibodies: A pilot study of treatment with intravenous immunoglobulin. Acta Obstet Gynecol Scand 1996;75:922-926.
75. Jablonowska B, Palfi M, Matthiesen L, Selbing A, Kjellberg S, Ernerudh J. T and B lymphocyte subsets in patients with unexplained recurrent spontaneous abortion: IVIG versus placebo treatment. Am J Reprod Immunol 2002;48:312-318.
76. Sturfelt G, Mousa F, Jonsson H, Nived O, Thysell H, Wollheim F. Recurrent cerebral infarction and the antiphospholipid syndrome: Effect of intravenous gammaglobulin in a patient with systemic lupus erythematosus. Ann Rheum Dis 1990;49:939-941.
77. Takagi M, Shigekiyo T. Gammaglobulin infusion therapy in a patient with antiphospholipid syndrome. Rinsho Ketsueki 1993;34:496-498.
78. Arnout J, Spitz B, Wittevrongel C, Vanrusselt M, Van Assche A, Vermylen J. High-dose intravenous immunoglobulin treatment of a pregnant patient with an antiphospholipid syndrome: Immunological changes associated with a successful outcome. Thromb Haemost 1994;71:741-747.
79. Cohen MG, Lui SF. Multiple complications of the antiphospholipid. syndrome with apparent response to aspirin therapy. J Rheumatol 1992;19:803-806.
80. Vandenberghe P, Zachee P, Verstraete S, Demuynck H, Boogaerts MA, Verhoef GE. Successful control of refractory and life-threatening autoimmune hemolytic anemia with intravenous immunoglobulins in a man with the primary antiphospholipid syndrome. Ann Hematol 1996;73:253-256.
81. Carp HJ, Asherson RA, Shoenfeld Y. Intravenous immunoglobulin in pregnancies complicated by the antiphospholipid syndrome: What is its role? J Clin Rheumatol 2001:291-294.
82. Konova E, Andreeva H, Petrova P, Mussa E, Kovacheva K, Popovsky K, et al. Intravenous Immunoglobulin in the treatment of the antiphospholipid-associated miscarriages - our experience. Clin Appl Immunol Investig 2001;1:75-79.
83. Sherer Y, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology (Oxford) 2000;39:421-426.
84. Carp HJ, Toder V, Gazit E, Ahiron R, Torchinski A, Mashiach S, et al. Further experience with intravenous immunoglobulin in women with recurrent miscarriage and a poor prognosis. Am J Reprod Immunol 2001;46:268-273.
85. Carp HJ, Ahiron R, Mashiach S, Schonfeld Y, Gazit E, Toder V. Intravenous immunoglobulin in women with five or more abortions. Am J Reprod Immunol 1996;35:360-362.
86. Jayne DR. Intravenous immunoglobulin as immuno-modifying treatment. In: Kallenberg CGM CJ, editor. Disease-modifying therapy in vasculitides. 2001. p 81-110.
87. Jayne DR, Esnault VL, Lockwood CM. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J Autoimmun 1993;6:207-219.
88. Jordan SC, Toyoda M. Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin. Clin Exp Immunol 1994;97(Suppl. 1):31-38.
89. Lockwood CM. New treatment strategies for systemic vasculitis: The role of intravenous immune globulin therapy. Clin Exp Immunol 1996;104(Suppl. 1):77-82.
90. Richter C, Schnabel A, Csernok E, De Groot K, Reinhold-Keller E, Gross WL. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 1995;101:2-7.
91. Thomas-Golbanov C, Sridharan S. Novel therapies in vasculitis. Expert Opin Investig Drugs 2001;10:1279-1289.
92. Levy Y, George J, Fabbrizzi F, Rotman P, Paz Y, Shoenfeld Y. Marked improvement of Churg-Strauss vasculitis with intravenous gammaglobulins. South Med J 1999;92:412-414.
93. Levy Y, Sherer Y, George J, Langevitz P, Ahmed A, Bar-Dayan Y, et al. Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol 1999;119:231-238.
94. Amital H, Levy Y, Shoenfeld Y. Use of intravenous immunoglobulin in livedo vasculitis. Clin Exp Rheumatol 2000;18:404-406.
95. Levy Y, Uziel Y, Zandman GG, Amital H, Sherer Y, Langevitz P, et al. Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann Rheum Dis 2003;62:1221-1223.
96. Molina V, Blank M, Shoenfeld Y. Fibrotic diseases. Harefuah 2002:1009.
97. Levy Y, Sherer Y, Langevitz P, Lorber M, Rotman P, Fabrizzi F, et al. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin - a preliminary report. Clin Rheumatol 2000;19:207-211.
98. Levy Y, Amital H, Langevitz P, Nacci F, Righi A, Conforti L, et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: An open-label study. Arthritis Rheum 2004;50:1005-1007.
99. Amital H, Rewald E, Levy Y, Bar-Dayan Y, Manthorpe R, Engervall P, et al. Fibrosis regression induced by intravenous gammaglobulin treatment. Ann Rheum Dis 2003;62:175-177.
100. Antonelli A, Navarranne A, Palla R, Alberti B, Saracino A, Mestre C, et al. Pretibial myxedema and high-dose intravenous immunoglobulin treatment. Thyroid 1994;4:399-408.
101. Utech CI, Khatibnia U, Winter PF, Wulle KG. MR T2 relaxation time for the assessment of retrobulbar inflammation in Graves' ophthalmopathy. Thyroid 1995;5:185-193.
102. Antonelli A, Melosi A, Saracino A, Alberti B, Agostini S, Neri S, et al. Parameters of organ-specific and non-specific autoimmunity in patients with Basedow's disease and Basedow's ophthalmopathy. Changes induced by IVIG treatment. Clin Ter 1992;141:49-54.
103. Leibe A, Levy Y, Shoenfeld Y. Intravenous immunoglobulins treatment of patients with Graves' ophthalmopathy. Harefuah 2001;140:392-394, 455, 454.
104. Blank M, Cities DB, Arepally G, Eldor A, Afek A, Shoenfeld Y. Pathogenicity of human anti-platelet factor 4 (PF4)/heparin in vivo: Generation of mouse anti-PF4/heparin and induction of thrombocytopenia by heparin. Clin Exp Immunol 1997;108:333-339.
105. Nurden AT, Laroche-Traineau J, Jallu V, Broult J, Durrien C, Besse P. Heparin-induced thrombocytopenia: Observations on the nature of the antibody activities and on the use of gammaglobulin concentrates in a patient with thrombotic complications. Thromb Haemost 1991;65:796.
106. Frame JN, Mulvey KP, Phares JC, Anderson MJ. Correction of severe heparin-associated thrombocytopenia with intravenous immunoglobulin. Ann Intern Med 1989;111:946-947.
107. Grau E, Linares M, Olaso MA, Ruvira J, Sanchis J. Heparin-induced thrombocytopenia - response to intravenous immunoglobulin in vivo and in vitro. Am J Hematol 1992;39:312-313.
108. Vender JS, Matthew EB, Silverman IM, Konowitz H, Dau PC. Heparin-associated thrombocytopenia: Alternative managements. Anesth Analg 1986;65:520-522.
109. Winder A, Shoenfeld Y, Hochman R, Keren G, Levy Y, Eldor A. High-dose intravenous gamma-globulins for heparin-induced thrombocytopenia: A prompt response. J Clin Immunol 1998;18:330-334.
110. Sherer Y, Levy Y, Fabbrizzi F, Shoenfeld Y. Treatment of hematologic disorders other than immune thrombocytopenic purpura with intravenous immunoglobulin (IVIg) - report of seven cases and review of the literature. Eur J Intern Med 2000;11:85-88.
111. Levy Y, Sherer Y, George J, Fabbrizzi F, Shoenfeld Y. Use of intravenous immunoglobulin in idiopathic membranous nephropathy. Intern Med 1999;38:917.
112. Fishman P, Shoenfeld Y. Intravenous immunoglobulin (IVIG) as an inhibitor of tumor growth: From autoimmunity to cancer. Old Herborn University Seminar Monograph, 2001. p 93-107.
113. Sherer Y, Levy Y, Shoenfeld Y. IVIG in autoimmunity and cancer - efficacy versus safety. Expert Opin Drug Saf 2002;1:153-158.
114. Shoenfeld Y, Levy Y, Fishman P. Shrinkage of melanoma metastases following high dose intravenous immunoglobulin treatment. Isr Med Assoc J 2001;3:698-699.
115. Krause I, Blank M, Shoenfeld Y. Anti-DNA and anti-phospholipid antibodies in IVIG preparations: In vivo study in naive mice. J Clin Immunol 1998;18:52-60.
116. Terryberry JW, Shoenfeld Y, Sherer Y, Levy Y, Fabrizzi F, Ahmed A, et al. Detection of antibodies to gangliosides and glycolipids in various intravenous immunoglobulin (IVIg) preparations. Immunol Investig 2000;29:337-347.
117. Sherer Y, Wu R, Kraus I, Peter JB, Shoenfeld Y. Anti-phospholipid antibody levels in intravenous immunoglobulin (IVIg) preparations. Lupus 2001;10:568-570.
118. Zaidan R, Al Moallem M, Wani BA, Shameena AR, Al Tahan AR, Daif AK, et al. Thrombosis complicating high dose intravenous immunoglobulin: Report of three cases and review of the literature. Eur J Neurol 2003;10:367-372.
119. Brown HC, Ballas ZK. Acute thromboembolic events associated with intravenous immunoglobulin infusion in antibody-deficient patients. J Allergy Clin Immunol 2003;112:797-799.
120. Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology 2002;59:S28-S32.
121. Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology 2001;62:133-137.
122. Razvi S, Schneider L, Jonas MM, Cunningham-Rundles C. Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency. Clin Immunol 2001;101:284-288.
123. Miller JL, Petteway Jr, SR, Lee DC. Ensuring the pathogen safety of intravenous immunoglobulin and other human plasma-derived therapeutic proteins. J Allergy Clin Immunol 2001;108:S91-S94.
124. Kessary-Shoham H, Levy Y, Shoenfeld Y, Lorber M, Gershon H. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. J Autoimmun 1999;13:129-135.
125. Dalakas MC, Clark WM. Strokes, thromboembolic events, and IVIg: Rare incidents blemish an excellent safety record. Neurology 2003;60:1736-1737.
126. Brennan VM, Salome-Bentley NJ, Chapel HM. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 2003;133:247-251.
127. Stangel M, Kiefer R, Pette M, Smolka MN, Marx P, Gold R. Side effects of intravenous immunoglobulins in neurological autoimmune disorders - a prospective study. J Neurol 2003;250:818-821.